Cathie Wood has recently increased her stakes in Figma, Arcturus Therapeutics, and 10x Genomics, despite a challenging week for the broader market, which saw major indexes decline for the fourth consecutive week. Figma, which has experienced an 83% drop from its peak last year, is facing slowing growth projections, yet it reported a 40% year-over-year revenue increase in its latest quarter. Arcturus, while struggling with declining revenues, is bolstered by promising clinical candidates and a strong cash position extending its runway to 2028.
These investments highlight Wood’s strategy of capitalizing on pullbacks in stocks she believes have long-term potential. Figma’s strong customer retention and revenue growth, despite margin pressures, and Arcturus’s innovative mRNA technology could position them favorably in their respective sectors.
For market professionals, the key takeaway is to monitor Wood’s selective buying approach, as it may signal confidence in these companies’ long-term growth prospects, even amid current volatility.
Source: nasdaq.com